Gait analysis is gaining attention as a non-invasive way to study changes associated with cognitive decline. Walking is not purely a motor task: it requires attention, planning, balance, visuospatial processing and the ability to adapt to changing surroundings. When these systems are affected, walking may become slower, less consistent or more cognitively demanding.
That does not mean gait analysis can confirm Alzheimer’s disease on its own. As of 2026, it is best understood as a screening and monitoring aid that may help clinicians decide whether a person needs a more complete cognitive and neurological assessment. Ageing, arthritis, stroke, Parkinson’s disease, vision loss, medication effects and fear of falling can produce similar changes. Any result must therefore be interpreted alongside medical history, cognitive testing and examination.
What gait analysis measures
A gait assessment examines how a person moves during normal walking and, in some studies, while performing a second task such as counting backwards. Common measures include:
- Walking speed: Slower speed can reflect reduced strength, confidence, attention or executive function.
- Step and stride length: Shorter steps may indicate impaired balance, motor planning or musculoskeletal limitation.
- Cadence: The number of steps per minute helps describe walking rhythm.
- Step-time and stride-time variability: Irregular timing can indicate reduced control and difficulty maintaining a stable walking pattern.
- Double-support time: Spending longer with both feet on the ground may reflect compensation for instability.
- Turning performance: Hesitation, extra steps or wide turns can reveal balance and planning problems.
- Dual-task cost: The change in gait when walking and completing a mental task at the same time can expose limited attentional reserve.
A single unusual walk is rarely meaningful. Repeated measurements under similar conditions are more useful because they distinguish a persistent change from fatigue, pain or an unfamiliar testing environment.
How gait changes may relate to Alzheimer’s
Alzheimer’s primarily affects memory and other cognitive functions, but the disease can also disrupt networks involved in spatial orientation, attention and movement planning. Research has associated cognitive decline with combinations of slower walking, shorter strides, increased variability and poorer performance during dual-task walking.
The pattern matters more than any one measurement. For example, a person who walks slowly because of knee osteoarthritis may have a stable, symmetrical gait. Someone with emerging cognitive impairment may show inconsistent step timing, difficulty turning, or a disproportionate decline when asked to talk while walking. These observations are clues, not proof of Alzheimer’s.
Gait findings may also differ across dementia types. Prominent balance problems, shuffling, freezing or marked asymmetry can point clinicians toward other neurological or vascular causes. This is one reason gait analysis should support—not replace—a differential diagnosis.
Technologies used in 2026
Gait testing ranges from a simple timed walk in a clinic to continuous monitoring at home. The appropriate option depends on the clinical question, budget and required level of precision.
- Timed walking tests: Low-cost assessments such as a short walk, repeated chair rise and turning task can be performed in primary-care or community settings.
- Instrumented walkways and pressure mats: These measure foot placement, timing, pressure distribution and stance phases with greater precision.
- Wearable inertial sensors: Accelerometers and gyroscopes attached to the feet, shins, waist or trunk can capture walking in clinics and real-world environments.
- Camera-based systems: Video and markerless motion capture estimate posture, joint movement and gait events. They require careful consent and privacy controls.
- Smartphone and home monitoring: Phones or ambient sensors may identify changes over weeks or months, although device placement, adherence and household layout affect data quality.
- Machine-learning models: Algorithms can combine gait features and cognitive-task performance to identify patterns associated with impairment. They should be validated on populations that reflect the intended users, including older adults in India.
Computer-vision systems raise additional concerns. Clinics and developers should minimise identifiable video, encrypt data, define retention periods and explain whether information is used for research or commercial model training. Technical accuracy is not enough if the system is difficult to use or produces results patients cannot understand.
A practical clinical workflow
A responsible workflow starts with a clear purpose: screening, tracking progression, assessing fall risk or evaluating response to an intervention. The assessor should record footwear, walking surface, assistive devices, recent falls, pain, fatigue, vision, medications and relevant neurological history.
A useful protocol may include normal walking, turns, standing balance and a dual-task condition. Repeat testing should use the same instructions and, where possible, the same device. Results should be compared with age-appropriate reference data rather than an arbitrary universal threshold.
If concerning changes appear, the next step is a clinician-led evaluation. This may include cognitive screening, functional history from a family member, medication review, neurological examination, blood tests and—when appropriate—brain imaging or specialist referral. Gait analysis can help prioritise evaluation, but it cannot determine whether an individual has Alzheimer’s, mild cognitive impairment or another condition.
For Indian healthcare providers, deployment should also account for multilingual instructions, barefoot or varied footwear, uneven surfaces, crowded clinics, low-bandwidth connectivity and differences in access to neurologists. A model trained only on controlled laboratory walks from high-income countries may not generalise to Indian homes and community settings.
Benefits and limitations
Potential benefits include:
- Earlier referral: Subtle movement changes may prompt cognitive assessment before a crisis such as a fall.
- Objective monitoring: Repeated measurements can complement patient and caregiver observations.
- Remote assessment: Home-based tools may extend monitoring to people who cannot frequently travel.
- Fall-risk management: The same data can guide physiotherapy, strength training and home-safety changes.
Important limitations remain:
- Gait changes are not specific to Alzheimer’s disease.
- Results vary with pain, footwear, mood, medication, environment and motivation.
- Small or biased datasets can produce unreliable AI predictions.
- Continuous monitoring raises consent, privacy and data-ownership questions.
- False positives may cause anxiety, unnecessary testing or inappropriate treatment.
Healthcare organisations evaluating a system should ask for sensitivity, specificity, calibration, subgroup performance, external validation and evidence from real-world settings. They should also require a clear escalation pathway when the tool flags risk.
What patients and caregivers should do
Do not self-diagnose from a slower walk or an app score. If walking has changed alongside memory problems, getting lost, difficulty managing finances, repeated falls or trouble with familiar tasks, arrange an assessment with a qualified clinician. Bring a medication list and note when the changes began, whether they fluctuate and whether pain or illness affects mobility.
A gait assessment can be valuable even when Alzheimer’s is not the cause. It may uncover treatable vision, balance, medication or musculoskeletal issues and support practical fall-prevention measures.
The outlook
The strongest future systems will combine gait with cognitive testing, speech, sleep, medical history and functional data rather than treating walking as a single diagnostic signal. Developers should prioritise transparent models, prospective validation and clinically meaningful outcomes such as safer mobility and faster referral—not just high accuracy on a laboratory dataset.
Gait analysis is therefore best positioned as an accessible piece of a broader cognitive-health pathway. Used carefully, it can help identify change earlier and support monitoring; used alone, it risks confusing a useful warning sign with a diagnosis.